How to Get Trulicity in Kentucky: Prescriptions, Telehealth, and Pharmacy Access

What Is Trulicity and Why Kentucky Patients Seek It

Trulicity is a branded GLP-1 receptor agonist containing dulaglutide, injected once weekly under the skin to lower blood glucose in adults with type 2 diabetes. The FDA approved dulaglutide in October 2014 based on the AWARD clinical program, which included eight randomized trials across thousands of patients [1]. Beyond glucose control, the REWIND trial (N=9,901) published in The Lancet in 2019 demonstrated a statistically significant 12% relative risk reduction in major adverse cardiovascular events (MACE) compared with placebo over a median follow-up of 5.4 years (HR 0.88 to 95% CI 0.79, 0.99, P<0.05), making dulaglutide a preferred agent for patients with type 2 diabetes who also carry cardiovascular risk [2].

The American Diabetes Association's 2024 Standards of Care in Diabetes state that "in patients with type 2 diabetes and established cardiovascular disease or indicators of high cardiovascular risk, a GLP-1 receptor agonist with demonstrated cardiovascular benefit is recommended as part of the glucose-lowering regimen" [3]. Dulaglutide is one of the agents specifically named in that recommendation.

Kentucky has a high burden of type 2 diabetes. The CDC's 2023 National Diabetes Statistics Report placed Kentucky among the states with adult diabetes prevalence above 13%, compared with the national average of 11.6% [4]. That patient load, combined with rural geography, makes telehealth-based prescribing especially relevant for Kentucky residents who may live hours from an endocrinologist.

How to Get a Trulicity Prescription in Kentucky

Getting a Trulicity prescription in Kentucky requires a licensed prescriber who has conducted a clinical evaluation, reviewed your relevant history, and determined that dulaglutide is appropriate for your condition. That evaluation can happen in person or via telehealth.

Step 1: Clinical evaluation. Your provider will confirm a type 2 diabetes diagnosis (fasting glucose ≥126 mg/dL on two separate occasions, or HbA1c ≥6.5%, per ADA criteria [3]) and review contraindications. Trulicity carries a boxed warning for a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [1].

Step 2: Baseline labs. Most prescribers order HbA1c, comprehensive metabolic panel (including renal function, because eGFR guides dose decisions), lipid panel, and a urine albumin-to-creatinine ratio. Thyroid function testing is not required by the label but is common practice when a thyroid nodule is present. The National Kidney Foundation notes that GLP-1 receptor agonists are generally safe above an eGFR of 15 mL/min/1.73m², but close monitoring is recommended in advanced chronic kidney disease [5].

Step 3: Prescription and prior authorization. Commercial plans almost universally require prior authorization before they will cover Trulicity. Step-therapy requirements often mandate a trial of metformin and one other oral agent first. Your provider's office submits the PA request, typically using the insurer's criteria that mirror the FDA label [1] and ADA guidelines [3].

Step 4: Pharmacy dispensing. Once authorized, a retail pharmacy fills the prescription. Most major chains in Kentucky (Walgreens, CVS, Kroger Pharmacy, Walmart Pharmacy) stock dulaglutide autoinjector pens, though availability of the 3.0 mg and 4.5 mg strengths may require a 24 to 48 hour order at rural locations.

The whole process from first telehealth visit to injection typically runs 3, 10 business days when prior authorization is needed, or 24 to 48 hours when a patient pays cash and prior authorization is waived.

Telehealth Prescribing of Trulicity in Kentucky

Telehealth prescribing of Trulicity is permitted in Kentucky, and several national platforms hold licenses to practice in the state. Kentucky law (KRS Chapter 311.550 et seq.) defines telehealth as the use of interactive audio, video, or other electronic media for clinical services, and allows prescribing of controlled and non-controlled substances following a valid patient-provider relationship established via that modality [6].

Dulaglutide is not a controlled substance, which removes the additional DEA-registration complexity that applies to weight-loss medications like phentermine. A Kentucky-licensed telehealth prescriber can send a Trulicity prescription directly to any retail pharmacy in the state or to a mail-order pharmacy.

How HealthRX's telehealth intake works for Kentucky patients:

1. Complete a health intake form (15 to 20 minutes) covering diabetes history, current medications, HbA1c, and cardiovascular risk factors.
2. Upload or authorize transfer of recent labs (within 90 days for HbA1c, within 6 months for CMP).
3. Synchronous video visit with a Kentucky-licensed provider (typically 20 to 30 minutes).
4. If appropriate, the provider sends a Trulicity e-prescription to your chosen Kentucky pharmacy or arranges mail-order delivery.
5. Follow-up is scheduled at 4 to 6 weeks to assess tolerability and glucose response.

The American Telemedicine Association's clinical guidelines for diabetes care note that asynchronous and synchronous telehealth modalities produce equivalent HbA1c reductions to in-person care in most patient populations when structured appropriately [7]. A 2022 analysis in JAMA Network Open (N=4,312 patients with type 2 diabetes) found that telehealth-delivered diabetes management reduced mean HbA1c by 0.82 percentage points over 12 months, comparable to in-person cohort results in the same health system [8].

Who Can Prescribe Trulicity in Kentucky

In Kentucky, prescriptive authority for dulaglutide extends to the following licensed clinician types.

Physicians (MD and DO): Full independent prescribing authority under KRS 311.550. Any physician licensed in Kentucky with an active DEA number and state medical license can prescribe Trulicity.

Advanced Practice Registered Nurses (APRNs) / Nurse Practitioners: Kentucky APRNs who hold a collaborative agreement with a supervising physician have prescriptive authority for non-controlled substances including dulaglutide under KRS 314.011 [6]. Kentucky moved toward expanded APRN practice authority in 2022, allowing APRNs with more than 4 years of collaborative practice experience to apply for independent prescribing status.

Physician Assistants (PAs): PAs in Kentucky prescribe under a supervision agreement with a collaborating physician per KRS 311.840. That agreement must specify the categories of drugs the PA may prescribe, and dulaglutide is routinely included in standard diabetes management agreements.

Endocrinologists: Preferred for complex cases (brittle diabetes, coexisting thyroid disease, BMI <27 with uncertain GLP-1 benefit), but not required. Primary care providers prescribe the majority of GLP-1 receptor agonist prescriptions nationally. A 2021 IQVIA analysis found that family medicine and internal medicine physicians wrote approximately 68% of all GLP-1 prescriptions in the United States.

Prior Authorization for Trulicity in Kentucky: What Documentation You Need

Prior authorization is the single biggest delay in Kentucky patients receiving Trulicity. Most commercial insurers operating in Kentucky, including Anthem BlueCross BlueShield of Kentucky, Humana, and Aetna, require a PA before covering dulaglutide.

Standard PA documentation requirements include:

• Confirmed type 2 diabetes diagnosis with HbA1c on file (usually ≥7.0% or ≥7.5% depending on plan)
• Documentation of metformin trial (or contraindication/intolerance to metformin)
• Trial of at least one additional oral agent (commonly a sulfonylurea or SGLT-2 inhibitor), unless contraindicated
• Current medication list showing the proposed dulaglutide dose
• Prescriber attestation that the patient has type 2 diabetes (not type 1) and does not have a personal or family history of MTC or MEN2

For cardiovascular indication support (which can sometimes bypass step therapy on certain plans), providers can include the REWIND trial data showing a statistically significant MACE reduction (HR 0.88, P<0.05) [2] and note that ADA 2024 guidelines explicitly recommend a GLP-1 RA with cardiovascular benefit in patients with established CVD [3].

Kentucky Medicaid (Medicaid managed care organizations including Aetna Better Health of Kentucky, Humana Healthy Horizons, Molina Healthcare, Passport Health Plan, and WellCare of Kentucky) does not currently cover Trulicity for type 2 diabetes. Medicaid formularies in the state favor metformin, sulfonylureas, and in some plans, SGLT-2 inhibitors, but dulaglutide does not appear on any Kentucky Medicaid preferred drug list as of the 2025 formulary cycle [9].

Patients on Kentucky Medicaid who need a GLP-1 receptor agonist may petition for a formulary exception with physician documentation of medical necessity, though approval rates are low without a documented cardiovascular indication.

Trulicity Pharmacies in Kentucky: Retail and Mail-Order Options

Any Kentucky-licensed retail pharmacy can fill a Trulicity prescription. The drug does not require a specialty pharmacy, though some plans route it there for cost management.

Retail chains with confirmed Kentucky stocking:

• Walgreens (statewide, 100+ locations)
• CVS Pharmacy (statewide)
• Kroger Pharmacy (strong presence in central and eastern Kentucky)
• Walmart Pharmacy (statewide, including rural locations)
• Rite Aid (limited Kentucky presence, primarily northern counties)

The 0.75 mg and 1.5 mg autoinjector pens are reliably stocked at most locations. The 3.0 mg and 4.5 mg pens are less commonly kept on shelf and may require 24 to 48 hours for ordering. Call ahead if you are on a higher dose.

Cash price without insurance: The list price for a four-pen (one-month supply) of Trulicity ranges from approximately $900 to $1,000, depending on strength. The Eli Lilly Insulin Value Program does not cover Trulicity, but Eli Lilly's Trulicity savings card reduces cost-sharing to as low as $25 per month for commercially insured patients who meet income criteria [10]. The Lilly Cares Foundation patient assistance program provides free medication to uninsured patients with household income below 400% of the federal poverty level [10].

Mail-order pharmacies: Express Scripts, OptumRx, and CVS Caremark mail-order all ship Trulicity to Kentucky addresses with appropriate cold-chain packaging. Dulaglutide must be refrigerated at 36°F, 46°F (2°C, 8°C) and can be stored at room temperature below 86°F (30°C) for up to 14 days once removed from refrigeration [1].

Transferring an Existing Trulicity Prescription to Kentucky

If you move to Kentucky or want to switch pharmacies within the state, transferring a Trulicity prescription is straightforward because dulaglutide is not a controlled substance. Kentucky pharmacy law (902 KAR 55:110) allows retail pharmacies to accept transferred non-controlled prescriptions from out-of-state pharmacies, and federal law allows a licensed Kentucky pharmacy to receive and fill such transfers.

To transfer: contact your new Kentucky pharmacy with the name and phone number of your previous pharmacy. The pharmacist handles the transfer electronically. If the prescription was issued by an out-of-state provider who is not licensed in Kentucky, you may need a new prescription from a Kentucky-licensed provider, which telehealth platforms can support in one business day in most cases.

Insurance coverage transfers with your plan; PA approvals are typically honored mid-authorization period if you stay on the same insurance plan. If you change insurance when moving to Kentucky, a new PA submission will usually be required.

503A Compounding Pharmacies and Dulaglutide in Kentucky

503A compounding pharmacies in Kentucky are licensed by the Kentucky Board of Pharmacy and may compound dulaglutide for individual patients under specific circumstances. A 503A pharmacy compounds for named patients based on a valid prescription and a documented clinical need that cannot be met by the commercially available product (for example, a dose or formulation not available from Eli Lilly).

The FDA does not recognize dulaglutide as currently on the drug shortage list, which means compounding of dulaglutide outside of patient-specific 503A scenarios lacks a clear federal regulatory basis [11]. The FDA's guidance on compounding of GLP-1 receptor agonists (updated 2025) distinguishes between semaglutide and tirzepatide (which were on shortage lists at various points) and other GLP-1 agents including dulaglutide [11].

Kentucky's 503A pharmacies may legally prepare patient-specific compounds when commercial drug is unavailable or when a prescriber documents a specific clinical need. Patients should verify that any Kentucky compounding pharmacy filling dulaglutide holds active licensure from the Kentucky Board of Pharmacy and, if shipping across state lines, holds non-resident pharmacy licensure in the destination state as well.

Dosing Schedule and Clinical Monitoring After Starting Trulicity

Starting dose for most patients is 0.75 mg once weekly, with titration to 1.5 mg after four weeks if tolerated and additional glycemic control is needed [1]. The AWARD-11 trial (N=1,842) demonstrated that escalation to 3.0 mg and 4.5 mg produced statistically significant additional HbA1c reductions of 0.54 and 0.71 percentage points respectively versus 1.5 mg, along with greater weight reduction [12].

After starting Trulicity, standard monitoring includes:

• HbA1c at 3 months after initiation or dose change
• Blood pressure and heart rate at each visit (GLP-1 RAs cause a modest heart rate increase of 1, 3 bpm on average [2])
• Renal function annually or more frequently if eGFR <60 mL/min/1.73m²
• Gastrointestinal symptom review at 4-week follow-up (nausea, vomiting, and diarrhea are the most common adverse effects, reported in approximately 12 to 21% of patients in AWARD trials [1])
• Pancreatitis assessment if the patient reports persistent severe abdominal pain

The ADA recommends reassessing glycemic therapy every 3 to 6 months and adjusting based on HbA1c trends, tolerability, cost, and comorbidities [3]. If HbA1c remains above goal at 1.5 mg after 12 weeks, titrate to 3.0 mg and reassess at 12 weeks before escalating further.

Patients in Kentucky with access to a pharmacist-led diabetes management program (available at some Kroger and independent pharmacies under collaborative practice agreements) can have HbA1c point-of-care testing and medication counseling done at the pharmacy, reducing the number of separate clinical visits required.